Auer S R, Monteiro I M, Reisberg B
Aging and Dementia Research Center, New York University Medical Center, New York, USA.
Int Psychogeriatr. 1996 Summer;8(2):247-66. doi: 10.1017/s1041610296002621.
A clinician should not rely entirely upon a caregiver's report regarding behavioral pathology when planning a treatment strategy. Direct observational evaluation instruments as well as caregiver-based assessments are necessary. A new scale for the empirical (observational) evaluation of behavioral symptoms in Alzheimer's disease (AD) and related dementias, the Empirical Behavioral Pathology in Alzheimer's Disease Rating Scale (E-BEHAVE-AD) was developed. Interrater reliability of this new assessment instrument was examined. Additionally, the relationship between the observed occurrence of behavioral symptomatology on this new rating instrument was compared with the occurrence using a similarly designed, caregiver-based instrument. The interrater reliability study consisted of two raters who simultaneously evaluated 20 dementia patients. The comparative study employed a cross-sectional design (N = 49). Individuals were evaluated in an outpatient clinic setting. The study population consisted of cognitively normal individuals and dementia patients. Evaluations included the new, observationally based behavioral assessment (the E-BEHAVE-AD), a caregiver-based behavioral assessment (the Behavioral Pathology in Alzheimer's Disease Rating Scale; BEHAVE-AD), a clinical global measure (the Global Deterioration Scale), and a mental status assessment (the Mini-Mental State Examination). The interrater reliability study revealed an intraclass correlation coefficient of .97 (p < .01) for total scores on the new E-BEHAVE-AD rating scale. The correlation coefficient for the amount of agreement on the presence of symptoms in six symptomatic categories between caregiver-based information about the patient's behavioral pathology assessed on the BEHAVE-AD and the clinician's observations assessed with the new E-BEHAVE-AD rating instrument was .51 (p < .01). The new E-BEHAVE-AD rating instrument showed excellent interrater reliability. Furthermore, there was a statistically significant relationship between clinician observation of the occurrence of behavioral pathology assessed using the E-BEHAVE-AD and caregiver-reported pathology assessed with the BEHAVE-AD. However, the magnitude of the correlation between these measures indicated that the majority of variance was independent and nonoverlapping. Consequently, these data support theoretical models suggesting that the assessment of behavioral pathology in dementia might ideally encompass both direct observational and caregiver-report approaches, using measures such as the E-BEHAVE-AD as well as measures such as the BEHAVE-AD.
在制定治疗策略时,临床医生不应完全依赖护理人员关于行为病理学的报告。直接观察评估工具以及基于护理人员的评估都是必要的。一种用于阿尔茨海默病(AD)及相关痴呆症行为症状实证(观察性)评估的新量表——阿尔茨海默病实证行为病理评定量表(E-BEHAVE-AD)被开发出来。对这种新评估工具的评分者间信度进行了检验。此外,还比较了在这个新评定工具上观察到的行为症状发生情况与使用类似设计的、基于护理人员的工具所观察到的行为症状发生情况之间的关系。评分者间信度研究由两名评分者组成,他们同时对20名痴呆症患者进行评估。比较研究采用横断面设计(N = 49)。个体在门诊环境中接受评估。研究人群包括认知正常个体和痴呆症患者。评估内容包括新的基于观察的行为评估(E-BEHAVE-AD)、基于护理人员的行为评估(阿尔茨海默病行为病理评定量表;BEHAVE-AD)、临床整体测量(总体衰退量表)和精神状态评估(简易精神状态检查表)。评分者间信度研究显示,新E-BEHAVE-AD评定量表总分的组内相关系数为0.97(p < 0.01)。基于护理人员在BEHAVE-AD上评估的患者行为病理信息与使用新E-BEHAVE-AD评定工具评估的临床医生观察结果之间,在六个症状类别中症状出现情况的一致程度的相关系数为0.51(p < 0.01)。新的E-BEHAVE-AD评定工具显示出极好的评分者间信度。此外,使用E-BEHAVE-AD评估的临床医生对行为病理发生情况的观察与使用BEHAVE-AD评估的护理人员报告的病理情况之间存在统计学上的显著关系。然而,这些测量之间的相关程度表明,大部分变异是独立且不重叠的。因此,这些数据支持了理论模型,表明痴呆症行为病理的评估理想情况下可能应同时包括直接观察和护理人员报告两种方法,使用诸如E-BEHAVE-AD这样的测量工具以及诸如BEHAVE-AD这样的测量工具。